Viewing Study NCT05103332

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:30 PM
Ignite Modification Date: 2026-05-27 @ 11:57 AM
Study NCT ID: NCT05103332
Status: COMPLETED
Last Update Posted: 2025-11-03
First Post: 2021-10-22
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
Sponsor: Alnylam Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hypertension View
Keywords:

Keywords

Keyword Brief Keyword Text View
None High blood pressure View
None Hypertension View
None Hypertensive View
None siRNA View
None Angiotensinogen View
None AGT View